Post-operative PainNano-ChitosanNCT07571837
Modulation of Periapical Inflammation Following Nano-sized Intracanal Medication. A Randomized Controlled Clinical Trial
A study testing Nanochitosan paste, Nano-calcium hydroxide paste and Calcium hydroxide paste in people with Post-operative Pain and Periapical Inflammation, run by Al-Azhar University at 1 site in Egypt.
Trial summary
The main cause of endodontic disorders is microbial infection. From the infected pulp tissue, microorganisms can penetrate into the deeper layers of root dentine and propagate a periapical tissue through the apical foramen and lateral canals causing apical periodontitis. Read more about this study
- Who is it for?
- Ages 20 to 40 years, men only
- Conditions the study is for
- Post-operative Pain, Periapical Inflammation
- What is being tested?
- Nanochitosan paste, Nano-calcium hydroxide paste and Calcium hydroxide paste
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 63 participants
- Where
- 1 siteEgypt
- Study dates
- 8 Oct 2026to 30 May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- Men only
- No healthy volunteers
- Adult
Who may be able to join
- Patients have single rooted teeth with root canal form type I. Have previous endodontic therapy with failure. Have periapical radiolucency (PAI score of 3 or 4). Asymptomatic patients who had no pain or swelling, had a negative response to palpation and percussion.
Who cannot join
- Patients who had received antibiotic therapy within the past 3 months. Pregnancy and lactation. Systemic disease. Physical or mental disability. Non-restorable teeth. Any signs of resorption, immature roots, fracture, sinus tract and dental anomaly
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Al Azhar University
Cairo, Nasr City, 11765
Sabah Morad Sobhy, PHD, 01096529143, sabamorad@yahoo.com
About this study
Official title: Modulation of Periapical Inflammation Following Nano-Calcium Hydroxide and Nano-Chitosan Intracanal Medications in Endodontic Retreatment Cases: A Randomized Controlled Clinical Trial
The main cause of endodontic disorders is microbial infection. From the infected pulp tissue, microorganisms can penetrate into the deeper layers of root dentine and propagate a periapical tissue through the apical foramen and lateral canals causing apical periodontitis. Apical periodontitis is an inflammatory condition affecting the periapical area of teeth with a global prevalence of 52% among individuals and 5% at tooth level. At the periapical region, microbes and their products encounter the host immune defense. Innate immune cells combat bacteria through phagocytosis and release anti-microbial substances, while adaptive immune cells initiate both cell-mediated and humoral immune responses. This immune activation also stimulates osteoclasts, leading to bone resorption and creating space for the inflammatory cells' infiltration . During periapical inflammation, immune cells migrate to the periapical area, where they release pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), along with anti-inflammatory cytokines like interleukin-10 (IL-10). These cytokines play crucial roles in modulating inflammation and tissue repair.
MicroRNAs (miRNAs) are evolutionarily conserved small (18-22 nucleotides) single-stranded, noncoding RNAs. It has been well acknowledged that miRNAs influence gene expression at the posttranscriptional level by targeting mRNA 3'-untranslated regions (3'-UTRs). Accumulating evidence has suggested that miRNA expression is related to the clinical and biological features of diverse diseases, and they can be potential biomarkers for diagnosis, treatment, and prognosis. miRNAs have revealed their critical roles in regulating various cellular functions, including proliferation, apoptosis, differentiation, metabolism, and tumorigenesis, by targeting specific mRNAs.
Read more
MiR-146a regulates innate immunity, inflammatory responses, and the antiviral pathway. Changes in miR-146a expression have been noted in many human diseases, including autoimmune disorders and cancers. In addition, miR-146a is an important biomarker of disease diagnosis, prevention, and treatment. It is a negative regulator of inflammatory responses by suppressing target gene expression. However, limited data is available regarding the functional role of miR-146a in modulating the inflammatory response of periapical tissues following root canal disinfection in endodontic retreatment cases.
Eliminating microorganisms is the primary objective of root canal therapy in order to create an environment as free of bacteria as possible. However, not all root canal treatments are completely successful, and in some cases, the infection persists leading to development of secondary apical periodontitis in previously treated teeth.
Disinfecting the root canal during retreatment is significantly more challenging due to the presence of persistent microorganisms that have settled in the root canal system. These microbes are often resistant to standard irrigations and antimicrobial agents leading to the formation of periradicular lesions. Such bacteria can survive for extended periods around the previously filled root canals. Sodium hypochlorite (NaOCl) is the most widely used irrigant in root canal therapy due to its strong antibacterial effect and its ability to dissolve organic substances. Effective canal cleaning is difficult to achieve without the use of NaOCl at a sufficiently high concentration. However, NaOCl has several drawbacks, including its cytotoxicity which can lead to tissue damage and patient symptoms. Additionally, its strong oxidizing nature negatively affects the mechanical properties of dentin such as microhardness and elastic modulus. NaOCl should be used with caution in endodontic procedures to prevent hypochlorite accidents.
Calcium hydroxide (Ca (OH)2) is the most widely utilized intracanal medication. It has the potential to dissolve tissue, acts as a physical barrier and generates hydroxyl ions, creating an extremely alkaline environment. It has been shown to be quite effective in the treatment of teeth with persistent periapical lesions. To provide optimal endodontic treatment, the root canal system should be thoroughly cleaned of soft-tissue debris, smear layer, and bacteria. Nanoparticles (NPs) have unique characteristics such as smaller sizes, increased surface area to volume ratio, and higher chemical reactivity and charge density leading to greater interaction with the environment and negatively charged bacterial cells, compared to their bulk counterparts. These advantages can be used to design highly anti-microbial agents with maximal therapeutic efficacy and minimal side effects.
Read the detailed description
Sixty-three patients will be divided randomly into three groups (21 patients in each group) using simple randomization procedure using random number generator. https://www.random.org/ based on intracanal medicament used. Sequentially numbered opaque sealed envelopes prepared in advance by an independent researcher will be used to prevent prediction of group assignment.
After application of local anesthesia (4% articaine with 1:100,000 epinephrine) and rubber dam isolation, the crown surfaces will be swabbed using 3% hydrogen peroxide, 5.25% sodium hypochlorite and 5% sodium thiosulphate before and after endodontic access. Gutta percha removal will be performed, the working length will be determined using an electronic apex locator (EAL) and will be confirmed using periapical radiograph, then the pre-instrumentation periapical samples (S1) will be gathered with a sterile #15 paper point. Root canal preparation will be performed using ProTaper Next nickel-titanium rotary system (Dentsply, Maillfer, Switzerland) driven by EndoEst motor mini (Geosoft Dent., Russia) endomotor till size X5 (50.05) file in continuous rotation at 300 rpm and 2 Ncm. After each file use, the root canal will be irrigated with 5ml of freshly prepared 2.5% sodium hypochlorite (NaOCl) solution (Alex. Deteregents and Chemical Co., Egypt) for 1 minute using a 31-gauge Navi-Tip flexible irrigating needle (Navi-Tip, Ultradent product, South Jourdan, UT). 5 ml of 17% EDTA (Colgate Oral Care Company, Waverly, Australia) for 1 min will be used for smear layer removal following saline separation. 5 ml of saline solution will be used for final irrigation of the root canal to neutralize all the previously used irrigants and post-instrumentation samples (S2) will be taken using #40 paper points.
Subsequently, three groups will be formed according to the predetermined group numbers based on intracanal medicament used. Group I: Nanochitosan paste (Nanogate company, Cairo, Egypt), Group II: Nano-calcium hydroxide paste (Nanogate company, Cairo, Egypt), Group III: Calcium hydroxide paste (MetaBiomed, Chungcheongbuk-do, Korea) in its regular form. Intracanal medicament will be placed in the canal, 1 mm shorter than the working length using the applicator tip and left for 1 week. The access cavity will be temporarily sealed with light cure glass ionomer resin cement. After 1 week, the temporary filling will be removed following local anaesthesia and isolation, the root canal will be irrigated with 20 ml saline and gently filed using H file corresponding to the master apical file size. The last sample (S3) will be collected using #40 paper points. During sampling, each paper point will be introduced into the canal 2 mm beyond the working length for 1 min. The root canals will be flushed with phosphate buffered saline (PBS) solution when blood or purulent discharge is detected or if the canal is dry and sampling will be repeated. The samples will be transferred in a sterile tube and stored at -80°C until processing(24).
The operator will be informed of the assigned group only immediately prior to medicament application. It will follow triple-blind design, in which the patient, outcome assessor and statistician are blinded to group allocation.
Finally, the root canal system will be obturated using ADSEAL resin-based sealer (Meta Biomed Co, Cheongju, Korea) and gutta-percha (Protaper next; Dentsply Maillefer, Switzerland) with cold lateral condensation method after being completely dried using paper points of comparable size to the master cone. A final coronal restoration with direct composite filling (Filtek Bulk Fill,3M ESPE, USA) will be performed in the same visit.
Potential harms include:
- Mild postoperative pain or discomfort
- Irritant reaction to irrigants or medicaments
- Temporary inflammation flare-up
Risk minimizing measures:
- Strict rubber dam isolation
- Standardized irrigation protocols
- Analgesic and antibiotic prescription if needed
An interim analysis will be conducted after 50% recruitment. The trial will be stopped early if:
- Severe adverse events exceed 10% in any group Statistically significant superiority or harm is detected
A data safety monitoring committee composed of an independent endodontist, pathologist, will oversee safety.
Adverse events will be documented at each visit and reported to the ethics committee within 48 hours for serious events.
Participants will be withdrawn in case of development of acute infection requiring antibiotics, severe pain requiring analgesics, failure to attend follow up appointment and protocol violation affecting outcome validity.
- Conditions
- Post-operative Pain, Periapical Inflammation
- Being tested
- Nanochitosan paste, Nano-calcium hydroxide paste, Calcium hydroxide paste
- Keywords
- Periapical Inflammation, Nano-Calcium Hydroxide, Nano-Chitosan, Endodontic Retreatment
- Medical subject headings
- Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nanochitosan pasteDrug
Nanochitosan paste (Nanogate company, Cairo, Egypt)
Nano-calcium hydroxide pasteDrug
Nano-calcium hydroxide paste (Nanogate company, Cairo, Egypt),
Calcium hydroxide pasteDrug
Calcium hydroxide paste (MetaBiomed, Chungcheongbuk-do, Korea)
| Study group | Role | What they receive |
|---|---|---|
| Group I: Nanochitosan paste | Experimental | Intracanal medicament will be placed in the canal, 1 mm shorter than the working length using the applicator tip and left for 1 week. Receives: Drug: Nanochitosan paste |
| Group II: Nano-calcium hydroxide paste | Experimental | Intracanal medicament will be placed in the canal, 1 mm shorter than the working length using the applicator tip and left for 1 week. Receives: Drug: Nano-calcium hydroxide paste |
| Group III: Calcium hydroxide paste | Experimental | Intracanal medicament will be placed in the canal, 1 mm shorter than the working length using the applicator tip and left for 1 week. Receives: Drug: Calcium hydroxide paste |
What is being measured
The primary outcome is the main question the study is designed to answer.
IL-10 and TNF-α levels
IL-10 and TNF-α levels will be quantified using ELISA kit from periapical fluid samples according to manufacturer instructions and regulatory miR-146a will be quantified using Real-time PCR
Measured: 1 week
Secondary outcomes (2)
Periapical cytological smear
Periapical cytological smear will be obtained using paper points. The paper points will be rolled onto a clean glass slide, stained and examined microscopically for the presence of inflammatory cells.
Measured: 1 week
Postoperative pain assessment
Pain intensity will be assessed using the Visual Analog Scale (VAS) on a 10-point scale (0 = no pain, 10 = worst pain imaginable) at the following timepoints:
- Pre-treatment (baseline).
- 6 hours post-treatment.
- 12 hours post-treatment.
- 1st day post-treatment.
- 2nd day post-treatment.
- 3rd day post-treatment.
- 7th day post-treatment.
Measured: 1 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2026
- Study start8 Oct 2026
- Primary completion15 Apr 2027 (estimated)
- Study completion30 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Post-operative PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 63 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Al-Azhar University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sabah Morad Sobhy, Al-Azhar University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07571837
- Sponsor's protocol ID
- P-PD-26-15
- Acronym
- Nano-Chitosan
- Status last verified
- Oct 2026
- First submitted
- 15 Mar 2026
- Last updated
- 15 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Cicek E, Kocak MM, Kocak S, Saglam BC, Turker SA. Postoperative pain intensity after using different instrumentation techniques: a randomized clinical study. J Appl Oral Sci. 2017 Jan-Feb;25(1):20-26. doi: 10.1590/1678-77572016-0138.
PubMed 28198972Zand V, Mokhtari H, Hasani A, Jabbari G. Comparison of the Penetration Depth of Conventional and Nano-Particle Calcium Hydroxide into Dentinal Tubules. Iran Endod J. 2017 Summer;12(3):366-370. doi: 10.22037/iej.v12i3.16421.
PubMed 28808467Waltimo T, Trope M, Haapasalo M, Orstavik D. Clinical efficacy of treatment procedures in endodontic infection control and one year follow-up of periapical healing. J Endod. 2005 Dec;31(12):863-6. doi: 10.1097/01.don.0000164856.27920.85.
PubMed 16306819Shrestha A, Kishen A. Antibacterial Nanoparticles in Endodontics: A Review. J Endod. 2016 Oct;42(10):1417-26. doi: 10.1016/j.joen.2016.05.021. Epub 2016 Aug 9.
PubMed 27520408
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Modulation of Periapical Inflammation Following Nano-Calcium Hydroxide and Nano-Chitosan Intracanal Medications in Endodontic Retreatment Cases: A Randomized Controlled Clinical Trial
- ClinicalTrials.gov ID
- NCT07571837
- Acronym / sponsor ID
- Nano-Chitosan / P-PD-26-15
- Conditions
- Post-operative Pain, Periapical Inflammation
- Keywords
- Periapical Inflammation, Nano-Calcium Hydroxide, Nano-Chitosan, Endodontic Retreatment
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 63 participants (estimated)
- Lead sponsor
- Al-Azhar UniversityUniversity, hospital or other
- Study start
- 8 Oct 2026 (actual)
- Primary completion
- 15 Apr 2027 (estimated)
- Study completion
- 30 May 2027 (estimated)
- First posted
- 6 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main cause of endodontic disorders is microbial infection. From the infected pulp tissue, microorganisms can penetrate into the deeper layers of root dentine and propagate a periapical tissue through the apical foramen and lateral canals causing apical periodontitis. Apical periodontitis is an inflammatory condition affecting the periapical area of teeth with a global prevalence of 52% among individuals and 5% at tooth level. At the periapical region, microbes and their products encounter the host immune defense. Innate immune cells combat bacteria through phagocytosis and release anti-microbial substances, while adaptive immune cells initiate both cell-mediated and humoral immune responses. This immune activation also stimulates osteoclasts, leading to bone resorption and creating space for the inflammatory cells' infiltration . During periapical inflammation, immune cells migrate to the periapical area, where they release pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), along with anti-inflammatory cytokines like interleukin-10 (IL-10). These cytokines play crucial roles in modulating inflammation and tissue repair.
MicroRNAs (miRNAs) are evolutionarily conserved small (18-22 nucleotides) single-stranded, noncoding RNAs. It has been well acknowledged that miRNAs influence gene expression at the posttranscriptional level by targeting mRNA 3'-untranslated regions (3'-UTRs). Accumulating evidence has suggested that miRNA expression is related to the clinical and biological features of diverse diseases, and they can be potential biomarkers for diagnosis, treatment, and prognosis. miRNAs have revealed their critical roles in regulating various cellular functions, including proliferation, apoptosis, differentiation, metabolism, and tumorigenesis, by targeting specific mRNAs.
MiR-146a regulates innate immunity, inflammatory responses, and the antiviral pathway. Changes in miR-146a expression have been noted in many human diseases, including autoimmune disorders and cancers. In addition, miR-146a is an important biomarker of disease diagnosis, prevention, and treatment. It is a negative regulator of inflammatory responses by suppressing target gene expression. However, limited data is available regarding the functional role of miR-146a in modulating the inflammatory response of periapical tissues following root canal disinfection in endodontic retreatment cases.
Eliminating microorganisms is the primary objective of root canal therapy in order to create an environment as free of bacteria as possible. However, not all root canal treatments are completely successful, and in some cases, the infection persists leading to development of secondary apical periodontitis in previously treated teeth.
Disinfecting the root canal during retreatment is significantly more challenging due to the presence of persistent microorganisms that have settled in the root canal system. These microbes are often resistant to standard irrigations and antimicrobial agents leading to the formation of periradicular lesions. Such bacteria can survive for extended periods around the previously filled root canals. Sodium hypochlorite (NaOCl) is the most widely used irrigant in root canal therapy due to its strong antibacterial effect and its ability to dissolve organic substances. Effective canal cleaning is difficult to achieve without the use of NaOCl at a sufficiently high concentration. However, NaOCl has several drawbacks, including its cytotoxicity which can lead to tissue damage and patient symptoms. Additionally, its strong oxidizing nature negatively affects the mechanical properties of dentin such as microhardness and elastic modulus. NaOCl should be used with caution in endodontic procedures to prevent hypochlorite accidents.
Calcium hydroxide (Ca (OH)2) is the most widely utilized intracanal medication. It has the potential to dissolve tissue, acts as a physical barrier and generates hydroxyl ions, creating an extremely alkaline environment. It has been shown to be quite effective in the treatment of teeth with persistent periapical lesions. To provide optimal endodontic treatment, the root canal system should be thoroughly cleaned of soft-tissue debris, smear layer, and bacteria. Nanoparticles (NPs) have unique characteristics such as smaller sizes, increased surface area to volume ratio, and higher chemical reactivity and charge density leading to greater interaction with the environment and negatively charged bacterial cells, compared to their bulk counterparts. These advantages can be used to design highly anti-microbial agents with maximal therapeutic efficacy and minimal side effects.
Detailed description
Sixty-three patients will be divided randomly into three groups (21 patients in each group) using simple randomization procedure using random number generator. https://www.random.org/ based on intracanal medicament used. Sequentially numbered opaque sealed envelopes prepared in advance by an independent researcher will be used to prevent prediction of group assignment.
After application of local anesthesia (4% articaine with 1:100,000 epinephrine) and rubber dam isolation, the crown surfaces will be swabbed using 3% hydrogen peroxide, 5.25% sodium hypochlorite and 5% sodium thiosulphate before and after endodontic access. Gutta percha removal will be performed, the working length will be determined using an electronic apex locator (EAL) and will be confirmed using periapical radiograph, then the pre-instrumentation periapical samples (S1) will be gathered with a sterile #15 paper point. Root canal preparation will be performed using ProTaper Next nickel-titanium rotary system (Dentsply, Maillfer, Switzerland) driven by EndoEst motor mini (Geosoft Dent., Russia) endomotor till size X5 (50.05) file in continuous rotation at 300 rpm and 2 Ncm. After each file use, the root canal will be irrigated with 5ml of freshly prepared 2.5% sodium hypochlorite (NaOCl) solution (Alex. Deteregents and Chemical Co., Egypt) for 1 minute using a 31-gauge Navi-Tip flexible irrigating needle (Navi-Tip, Ultradent product, South Jourdan, UT). 5 ml of 17% EDTA (Colgate Oral Care Company, Waverly, Australia) for 1 min will be used for smear layer removal following saline separation. 5 ml of saline solution will be used for final irrigation of the root canal to neutralize all the previously used irrigants and post-instrumentation samples (S2) will be taken using #40 paper points.
Subsequently, three groups will be formed according to the predetermined group numbers based on intracanal medicament used. Group I: Nanochitosan paste (Nanogate company, Cairo, Egypt), Group II: Nano-calcium hydroxide paste (Nanogate company, Cairo, Egypt), Group III: Calcium hydroxide paste (MetaBiomed, Chungcheongbuk-do, Korea) in its regular form. Intracanal medicament will be placed in the canal, 1 mm shorter than the working length using the applicator tip and left for 1 week. The access cavity will be temporarily sealed with light cure glass ionomer resin cement. After 1 week, the temporary filling will be removed following local anaesthesia and isolation, the root canal will be irrigated with 20 ml saline and gently filed using H file corresponding to the master apical file size. The last sample (S3) will be collected using #40 paper points. During sampling, each paper point will be introduced into the canal 2 mm beyond the working length for 1 min. The root canals will be flushed with phosphate buffered saline (PBS) solution when blood or purulent discharge is detected or if the canal is dry and sampling will be repeated. The samples will be transferred in a sterile tube and stored at -80°C until processing(24).
The operator will be informed of the assigned group only immediately prior to medicament application. It will follow triple-blind design, in which the patient, outcome assessor and statistician are blinded to group allocation.
Finally, the root canal system will be obturated using ADSEAL resin-based sealer (Meta Biomed Co, Cheongju, Korea) and gutta-percha (Protaper next; Dentsply Maillefer, Switzerland) with cold lateral condensation method after being completely dried using paper points of comparable size to the master cone. A final coronal restoration with direct composite filling (Filtek Bulk Fill,3M ESPE, USA) will be performed in the same visit.
Potential harms include:
- Mild postoperative pain or discomfort
- Irritant reaction to irrigants or medicaments
- Temporary inflammation flare-up
Risk minimizing measures:
- Strict rubber dam isolation
- Standardized irrigation protocols
- Analgesic and antibiotic prescription if needed
An interim analysis will be conducted after 50% recruitment. The trial will be stopped early if:
- Severe adverse events exceed 10% in any group Statistically significant superiority or harm is detected
A data safety monitoring committee composed of an independent endodontist, pathologist, will oversee safety.
Adverse events will be documented at each visit and reported to the ethics committee within 48 hours for serious events.
Participants will be withdrawn in case of development of acute infection requiring antibiotics, severe pain requiring analgesics, failure to attend follow up appointment and protocol violation affecting outcome validity.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Group I: Nanochitosan paste | Experimental | Drug: Nanochitosan pasteIntracanal medicament will be placed in the canal, 1 mm shorter than the working length using the applicator tip and left for 1 week. |
| Group II: Nano-calcium hydroxide paste | Experimental | Drug: Nano-calcium hydroxide pasteIntracanal medicament will be placed in the canal, 1 mm shorter than the working length using the applicator tip and left for 1 week. |
| Group III: Calcium hydroxide paste | Experimental | Drug: Calcium hydroxide pasteIntracanal medicament will be placed in the canal, 1 mm shorter than the working length using the applicator tip and left for 1 week. |
Who may qualify
- Ages
- 20 to 40 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Patients have single rooted teeth with root canal form type I. Have previous endodontic therapy with failure. Have periapical radiolucency (PAI score of 3 or 4). Asymptomatic patients who had no pain or swelling, had a negative response to palpation and percussion.
Key exclusion criteria (1 listed)
- Patients who had received antibiotic therapy within the past 3 months. Pregnancy and lactation. Systemic disease. Physical or mental disability. Non-restorable teeth. Any signs of resorption, immature roots, fracture, sinus tract and dental anomaly
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nanochitosan pasteNanochitosan paste (Nanogate company, Cairo, Egypt) | Drug | Group I: Nanochitosan paste |
| Nano-calcium hydroxide pasteNano-calcium hydroxide paste (Nanogate company, Cairo, Egypt), | Drug | Group II: Nano-calcium hydroxide paste |
| Calcium hydroxide pasteCalcium hydroxide paste (MetaBiomed, Chungcheongbuk-do, Korea) | Drug | Group III: Calcium hydroxide paste |
Primary outcome
IL-10 and TNF-α levels
Time frame: 1 week
IL-10 and TNF-α levels will be quantified using ELISA kit from periapical fluid samples according to manufacturer instructions and regulatory miR-146a will be quantified using Real-time PCR
2 secondary outcomes
Periapical cytological smear
Time frame: 1 week
Postoperative pain assessment
Time frame: 1 week
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2026.
- Background: PubMed 28198972Cicek E, Kocak MM, Kocak S, Saglam BC, Turker SA. Postoperative pain intensity after using different instrumentation techniques: a randomized clinical study. J Appl Oral Sci. 2017 Jan-Feb;25(1):20-26. doi: 10.1590/1678-77572016-0138.
- Background: PubMed 28808467Zand V, Mokhtari H, Hasani A, Jabbari G. Comparison of the Penetration Depth of Conventional and Nano-Particle Calcium Hydroxide into Dentinal Tubules. Iran Endod J. 2017 Summer;12(3):366-370. doi: 10.22037/iej.v12i3.16421.
- Background: PubMed 16306819Waltimo T, Trope M, Haapasalo M, Orstavik D. Clinical efficacy of treatment procedures in endodontic infection control and one year follow-up of periapical healing. J Endod. 2005 Dec;31(12):863-6. doi: 10.1097/01.don.0000164856.27920.85.
- Background: PubMed 27520408Shrestha A, Kishen A. Antibacterial Nanoparticles in Endodontics: A Review. J Endod. 2016 Oct;42(10):1417-26. doi: 10.1016/j.joen.2016.05.021. Epub 2016 Aug 9.
- Individual participant dataSharing planned: No
Related trials for Post-operative Pain
Recruiting
Butyrate and Taurine for Chronic Postsurgical Pain in Adult Cardiac Surgical Patients
Pain, Acute, Pain, Chronic
Not yet recruiting
The IMPACT Study: Personalized Physical Therapy for Better Recovery and a Stronger Core After Hernia Surgery
Ventral Hernia, Ventral Incisional Hernia
RecruitingPhase 4
Comparing Analgesic Regimen Effectiveness and Safety for Surgery for Kids Trial
Surgery, Pain, Post Operative
Not yet recruiting
Post-operative Pain and Apical Healing After Root Canal (re)Treatment With Laser-activated Irrigation Versus Sonic or no Activation
Apical Periodontitis, Post Operative Pain, Acute
Not yet recruiting
Perioperative Mirogabalin for Pain Relief After Modified Radical Mastectomy
Breast Cancer, Post Operative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nanochitosan paste, Nano-calcium hydroxide paste and Calcium hydroxide paste in people with Post-operative Pain and Periapical Inflammation, run by Al-Azhar University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sabah Morad Sobhy, PHD (+201096529143, sabamorad@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
IL-10 and TNF-α levels (time frame: 1 week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07571837, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026; AzTrials last refreshed its copy on 26 Oct 2026.